Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
These data raise the possibility that at least for high risk patients treated with statins, follow-up could be simplified and expenses reduced if only apo B were measured. They also raise the possibility that outcome might be improved if the therapeutic algorithm were simplified.
Administration of DTP with, or after MV, may reduce the beneficial effect of MV.